Related Experiment Video

Updated: Feb 26, 2026

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment
11:13

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment

Published on: June 9, 2023

2.4K

Entinostat for the treatment of breast cancer

Dario Trapani1, Angela Esposito1, Carmen Criscitiello1

  • 1a Division of Early Drug Development , European Institute of Oncology , Milan , Italy.

Expert Opinion on Investigational Drugs
|July 19, 2017
PubMed
Abstract

Insights

Entinostat, a histone deacetylase inhibitor, shows promise in treating various breast cancer subtypes, including resistant forms. It may also enhance immunotherapy effectiveness by modulating the tumor immune microenvironment.

Area of Science:

  • Oncology
  • Epigenetics
  • Pharmacology

Background:

  • Breast cancer is a heterogeneous disease with diverse molecular subtypes.
  • Epigenetic alterations, including DNA and histone modifications, drive tumor progression and treatment resistance.
  • Histone deacetylases (HDACs) play a critical role in regulating gene expression and cellular processes in cancer.

Purpose of the Study:

  • To explore the therapeutic potential of entinostat in breast cancer treatment.
  • To review clinical trial data evaluating entinostat's efficacy across different breast cancer subtypes.
  • To assess entinostat's role in overcoming endocrine resistance and enhancing anti-tumor immunity.

Main Methods:

  • Review of preclinical data and early-phase clinical studies on entinostat.
  • Analysis of clinical trials investigating entinostat in endocrine-resistant, HER2-positive, and triple-negative breast cancer.
  • Evaluation of entinostat's impact on immune modulation and its combination potential with immunotherapy.

Main Results:

  • Entinostat, a class I HDAC inhibitor, demonstrates anti-proliferative and pro-apoptotic effects in breast cancer cells.
  • Clinical trials suggest entinostat combined with antiestrogen therapy can overcome resistance pathways, particularly in hormone-positive breast cancer.
  • Entinostat exhibits potential in modulating the immune system, offering a rationale for combination with immunotherapy.

Conclusions:

  • Epigenetic therapy with entinostat represents a promising strategy for managing breast cancer, especially in resistant cases.
  • Entinostat may enhance the efficacy of current therapies by targeting resistance mechanisms and boosting anti-tumor immunity.
  • Combining entinostat with immunotherapy, such as cancer vaccines, warrants further investigation for improved treatment outcomes.
Keywords:
HDACendocrine- resistanceentinostatepigenetic

More Related Videos

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?14:20

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Published on: June 13, 2014

17.2K
Live Imaging of Drug Responses in the Tumor Microenvironment in Mouse Models of Breast Cancer08:26

Live Imaging of Drug Responses in the Tumor Microenvironment in Mouse Models of Breast Cancer

Published on: March 24, 2013

25.5K

Related Concept Videos

Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.8K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.8K
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
10.3K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.0K
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates...
684
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.9K